Cardiol Therapeutics Inc

Company Profile

• Business description

  Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

• Contact

  2265 Upper Middle Road East
  Suite 602
  OakvilleONL6H 0G5
  CAN

  T: +1 289 910-0850

  E: [email protected]

  https://www.cardiolrx.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - Specialty & Generic

  Fiscal Year End

  31 December 2025

  Employees

  17